Medication company Viatris (NASDAQ:VTRS) will be reporting results tomorrow before market open. Here’s what to expect. Viatris beat analysts’ revenue expectations by 1% last quarter ...

In this article, we are going to take a look at where Viatris Inc. (NASDAQ:VTRS) stands against the other large-cap stocks. The big and large-cap stocks have spearheaded the rally in the past two ...

PITTSBURGH, Feb. 27, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that on February 24, 2025, its Board of Directors approved a 2025 dividend policy of 48 cents ($0.48 ...

Viatris has made a play to expand its branded medicines business by licensing two late-stage drugs from Idorsia – for acute myocardial infarction (AMI) and systemic lupus erythematosus (SLE ...

Viatris (NASDAQ:VTRS), a global healthcare company known for its broad portfolio of pharmaceutical products, released its fourth-quarter 2024 results on Feb. 27. Despite achieving substantial debt ...

Viatris (NASDAQ:VTRS) is scheduled to announce Q4 earnings results on Thursday, February 27th, before market open. SA analyses from early this year have ranged from cautious to optimistic ...

In this article, we are going to take a look at where Viatris Inc. (NASDAQ:VTRS) stands against the other stocks. Wall Street's main indices all finished in the green territory on Wednesday ...

CANONSBURG, Pa. (AP) — CANONSBURG, Pa. (AP) — Viatris Inc (VTRS) on Thursday reported a loss of $516.5 million in its fourth quarter. The Canonsburg, Pennsylvania-based company said it had a ...

Despite operational successes, Viatris faced a significant 71% drop in GAAP net earnings due to international market pressures. Viatris delivered a mixed quarter, topping earnings expectations but ...